A Phase I, Single Center, Double-Blind, Placebo-Controlled Dose Finding Clinical Study to Evaluate the Safety and Immunogenicity of the Live Attenuated, Oral Vaccine ACE527
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2015
At a glance
- Drugs ACE 527 (Primary)
- Indications Escherichia coli infections; Traveller's diarrhoea
- Focus Adverse reactions
- 30 Jan 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 30 Jan 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 13 May 2009 New trial record